Transdermal Drug Delivery
Technologies, Companies & Markets

By
Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

September 2020

A Jain PharmaBiotech Report
ABOUT THE AUTHOR

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.


ABOUT THIS REPORT

The original report on Transdermal Drug Delivery appeared as a section in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery as separate reports in 2000. In 2002, Transdermal Drug Delivery was also detached, expanded, and updated to be issued as separate publications by Jain PharmaBiotech. The report was regularly updated since 2002, enlarged and rewritten for 2020 edition.
## TABLE OF CONTENTS

0. Executive Summary ................................................................. 10

1. Basics of Transdermal Drug Delivery ........................................... 12
   Introduction ............................................................................... 12
   Histological landmarks in transdermal drug delivery .................. 12
   Anatomy and physiology of skin ............................................. 13
   Skin metabolismics and transcutaneous passage of drugs .............. 13
   Transcutaneous absorption ...................................................... 14
   Transdermal versus other methods of drug delivery .................... 14
     Advantages of transdermal drug delivery ................................. 14
     First-Pass Effect ..................................................................... 15
     Drawbacks of transdermal delivery ......................................... 15
   Factors that influence transdermal drug delivery ....................... 15
     Rate of permeation across the skin ........................................ 16
     Properties of the skin .......................................................... 16
     Properties of drugs .............................................................. 17
     The role of pH and pharmacokinetics ..................................... 18
     Intradermal disposition of drugs after topical application .......... 18
     Role of nanobiotechnology in understanding basis of transdermal delivery ......................................................... 18

2. Transdermal Drug Delivery Technologies ..................................... 20
   Introduction ............................................................................... 20
   Local application formulations ................................................. 21
     Crystalline topical formulations ............................................. 21
     Microemulsions for transdermal drug delivery ....................... 21
     Nanoemulsions for transdermal drug delivery ....................... 22
     Transdermal gel technology .................................................. 22
     Biphaxis system .................................................................... 24
   Penetration enhancers .............................................................. 24
     Chemical enhancers .............................................................. 24
     Nitric oxide-based transdermal drug delivery ......................... 26
     Ionic liquids for transdermal delivery of drugs against bacterial biofilms on skin ......................................................... 27
     Vesicular transdermal carriers ................................................. 27
     Ethosomes ............................................................................ 27
     Elastic vesicles for transdermal drug delivery ....................... 28
     Liposomes ............................................................................ 28
     Nanovesicles for transdermal drug delivery ......................... 29
     Transfersomes ..................................................................... 29
   Transdermal patches ................................................................. 30
     Adhesives for transdermal patches ......................................... 31
     Commercial development of transdermal patches .................... 32
     Innovations in transdermal patches ......................................... 33
     e-Patch™ controlled release micropump system ....................... 33
     Patchless Transdermal Delivery System .................................. 34
     Metered-dose transdermal system ........................................... 34
   Polymers for transdermal drug delivery ..................................... 35
     Polymer membranes in transdermal patches ............................ 35
     Film forming polymeric solutions .......................................... 36
     Crystal Reservoir System of Nitto Denko .................................. 36
   Use of physical modalities to facilitate transdermal transport ...... 37
     Transdermal electrotaxis ......................................................... 37
     Drug delivery by electroporation .......................................... 38
     Cryoelectrophoresis ............................................................. 39
     Iontophoresis ....................................................................... 40
     Iontophoresis compared with electrophoresis ........................ 40
     Application of iontophoresis for drug delivery .................... 41
     Patents in iontophoresis ....................................................... 41
     Companies with technologies for drug delivery by iontophoresis ................................................................. 42
     Combination of electrophoresis and iontophoresis .................. 43
     Dermaportation .................................................................... 43
     Radiofrequency-driven transdermal delivery ......................... 44
     Microporation ...................................................................... 44
     Transcutaneous drug delivery by electropulsation .................. 45
     Companies involved in electroporation-based drug delivery ...... 45
     Electrode Scanning System .................................................... 45
     Use of electrostatic force in skin patch technology ................. 46
Multiple Absorption Kinetic System

Transdermal drug delivery facilitated by heat

Controlled, heat-aided drug delivery

Ultrasound

Magnetophoresis

Use of lasers for transdermal drug delivery

Laser-induced microporation

Transdermal drug delivery by laser-induced pressure waves

Transdermal drug delivery by laser-assisted changes in skin

Transdermal delivery by gas under pressure

Transdermal delivery with PowderJect gas gun

Microneedle assisted microparticle delivery by a gene gun

Microscission induced by gas

Role of microelectronics in transdermal drug delivery

Microneedles and dermal microinjection technologies

Applications of microneedles

AdminPatch® microneedle array

Biodegradable microneedles

Ceramic microneedle arrays

Dissolvable microneedle patches

MicorCor

Microneedle arrays for drug delivery

Microneedle patch

MicroPyramid™ microneedles

Microstructured Transdermal Systems

Microneedle Array Patch technology

Microneedle transdermal chip

Microneedle applicator device

Nanoject™ microneedle technology

Nanoneedle patch

PatchPump

Polymer microneedles

Silk microneedles

Tattooing for drug delivery

ZP Patch microprojections technology

Companies developing microneedles for transdermal drug delivery

Needlefree injections

Glide SDI® solid dose injector

Jet injection

Mini-Ject needlefree delivery system

MicroJet for painless injections

Nanolitre-volume pulsed microjets

SUMAVEL™ DosePro™ needle-less injection

Skin ablation or abrasion for drug delivery

Nanotechnology-based transdermal drug delivery

Delivery of nanostructured drugs from transdermal patches

Effect of mechanical flexion on penetration of bucky balls through the skin

Nanobiotechnology for transdermal application

Nanoparticles and nanoemulsions for skin disorders

Nanogels

Nanopatches

Hyaluronic acid for facilitating transdermal passage of nanoconstructs

Ionic nanoparticle technology

SLN gel for treatment of skin disorders

Topical delivery of siRNA- nanoparticle conjugates

Transdermal nanoparticle preparations for systemic effect

Transdermal administration of nanocarriers

Nanotechnology-based transdermal vaccination and immunotherapy

Safety issues of applications of nanomaterial carriers on the skin

Comparison of transdermal drug delivery systems

In vitro testing of transdermal drug delivery systems

Commercially available skin models for transdermal drug testing

FDA guidelines for post-approval changes in semisolid topical drugs

In vivo testing of drug delivery systems

Infrared spectroscopy for evaluation of transdermal drug delivery

Methods for assessment of the performance of topically applied drugs

Modelling of transdermal drug delivery through the skin

Concluding remarks on transdermal drug delivery technologies

Future developments in transdermal drug delivery
3. Transdermal Therapeutics .............................................................. 78

Introduction ................................................................................. 78

Drugs that can be administered transdermally ................................ 78
Approved transdermal products ...................................................... 78
Drugs in clinical trials ................................................................. 80

Skin disorders ............................................................................. 81
Cutaneous leishmaniasis ............................................................... 81
Hair loss ...................................................................................... 81
Iontophoretic drug delivery for nail disorders ................................ 82
Psoriasis ...................................................................................... 82
Nanoemulsions for paclitaxel delivery in psoriasis ...................... 82

Cardiovascular disorders ............................................................ 82
Transdermal estrogen for prevention of atherosclerotic cardiovascular disease ...................................................... 82
Transdermal drug delivery for angina pectoris ................................ 83
Transdermal drug delivery for hypertension ............................... 84
Transdermal clonidine ................................................................... 85
Transdermal delivery of β-blockers for hypertension ................. 85
Transdermal delivery of calcium channel blockers for hypertension ................................................................. 85
Transdermal drug delivery for congestive heart failure ............ 86
Transdermal beta blockers .......................................................... 86
Transdermal anticoagulants ......................................................... 87

Respiratory diseases ................................................................ 87
Asthma ......................................................................................... 87
Chronic obstructive pulmonary disease ..................................... 88

Neurological and psychiatric disorders ...................................... 88
Parkinson's disease ..................................................................... 88
Transdermal drug delivery for Parkinson's disease .................... 89
Transdermal levodopa delivery systems ...................................... 89
Transdermal dopamine agonists for Parkinson's disease ........... 89
Rotigotine for Parkinson disease ............................................... 91
Rotigotine for restless legs syndrome ........................................ 92
Transdermal administration of other drugs for Parkinson disease ................................................................. 93
Depression .................................................................................. 93
Antidepressants ........................................................................ 93
Selective serotonin-reuptake inhibitors ...................................... 93
Transdermal fluoxetine ............................................................... 94
Monoamine oxidase inhibitors .................................................... 94
Transdermal selegiline ............................................................... 95
Trazodone hydrochloride ............................................................ 95
Venlafaxine ................................................................................ 96
Bupropion ................................................................................. 96

Bipolar disorder ....................................................................... 97
Transdermal lithium .................................................................. 97

Schizophrenia .......................................................................... 97
Transdermal haloperidol ............................................................. 97
Transdermal risperidone for treatment of schizophrenia ........ 98
Transdermal bupropion for treatment of schizophrenia ........... 98
Restless legs syndrome ............................................................. 98
Alzheimer's disease ................................................................... 99
Transdermal rivastigmine ........................................................... 99
Transdermal donepezil ............................................................. 99
Transdermal galantamine .......................................................... 100
Transdermal arecoline ............................................................. 100
Transdermal nicotine for Tourette syndrome ......................... 100
Attention deficit hyperactivity disorder .................................... 101

Migraine .................................................................................. 101
Transdermal sumatriptan .......................................................... 102
Transdermal zolmitriptan .......................................................... 103
Transdermal dihydroergotamine ................................................. 103

Epilepsy .................................................................................. 103
Tinnitus/Vertigo ........................................................................ 104
Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage ......................................................... 104

Musculoskeletal disorders ......................................................... 104
Osteoporosis .......................................................................... 104
Transdermal alendronate .......................................................... 104
Transdermal estrogen ............................................................... 105
Transdermal human parathyroid hormone .............................. 105
Osteoarthritis .......................................................................... 105

Transdermal therapy of diabetes .............................................. 106
Insulin delivery in diabetes by transdermal patches ................... 106
Microneedle patch for glucose-responsive insulin delivery ......................................................... 106
Patch monitoring system for insulin delivery ............................................................................... 107
Sonic Applicator & Control Device for TDD of insulin .............................................................. 108
V-Go® disposable insulin delivery device ...................................................................................... 108
ViaDor System for TDD of insulin ............................................................................................... 108
Companies developing devices for transdermal insulin delivery .............................................. 109
Transdermal therapy of oral antidiabetic agents ....................................................................... 108

Male disorders ............................................................................................................................. 110
Erectile dysfunction ..................................................................................................................... 110
Topical and transdermal preparation for erectile dysfunction ..................................................... 110
Hypogonadism in the male ........................................................................................................... 111
Topical testosterone ..................................................................................................................... 111
Benign prostatic hypertrophy ....................................................................................................... 113
Transdermal TDS ......................................................................................................................... 113
Tamsulosin TDS ........................................................................................................................... 113

Women's health ........................................................................................................................... 113
Female sexual arousal disorder .................................................................................................... 113
Menopause .................................................................................................................................... 113
Hormone replacement therapy for menopause .......................................................................... 114
Effect of transdermal estradiol on bone density ......................................................................... 116
Transdermal PTH for postmenopausal osteoporosis .................................................................. 116
Transdermal testosterone for low libido in postmenopausal women .......................................... 116
Breast disorders ........................................................................................................................... 117
Dysmenorrhea ............................................................................................................................... 117
Female infertility .......................................................................................................................... 117

Contraception ............................................................................................................................. 118
Female contraception .................................................................................................................. 118
Ortho Evra™ .............................................................................................................................. 118
AG200-15 ..................................................................................................................................... 119
BAY86-5016 .................................................................................................................................. 119
Desogestrel ................................................................................................................................... 119
Male contraception ........................................................................................................................ 119
Transdermal progestin plus testosterone .................................................................................... 119

Cancer ......................................................................................................................................... 120
Delivery of the photensitizer 8-amino levulonic acid ................................................................. 120
Intradermal delivery of cancer vaccines by adenoviral vectors .................................................. 120
Nanoemulsion-based delivery of caffeine for skin cancer ......................................................... 121
Topical interferon α2b for cervical cancer and precancerous lesions ......................................... 121
Transcutaneous electroporation for delivery of anticancer drugs .............................................. 121
Transdermal delivery of peptide cancer vaccines ...................................................................... 122
Transdermal drug delivery for prostate cancer .......................................................................... 122
Transdermal nitroglycerine for prostate cancer .......................................................................... 122
Transdermal estradiol gel for prostate cancer ............................................................................. 122
Transdermal leuprolide acetate for prostate cancer ..................................................................... 122
Transdermal drug delivery for breast cancer .............................................................................. 123
Afimoxifene topical gel for breast cancer .................................................................................... 123

Pain ........................................................................................................................................... 123
Relief of pain associated with minor medical procedures .......................................................... 123
Transdermal lidocaine: relief of postherpetic neuralgia ............................................................... 123
Lidoderm® .................................................................................................................................... 124
Lidopat® ........................................................................................................................................ 124
ZTliod .......................................................................................................................................... 124
Transdermal capsaicin for relief of pain ....................................................................................... 124
Nonsteroidal antinflammatory drugs ............................................................................................ 124
Topical NSAIDs ............................................................................................................................ 124
Transdermal ketoprofen ............................................................................................................... 125
Topical opioids ............................................................................................................................... 126
Cancer pain ................................................................................................................................. 127
Transdermal fentanyl ..................................................................................................................... 127
Transdermal nitroglycerine as an adjuvant to opioids ................................................................. 128
Transdermal buprenorphine ........................................................................................................ 128
Chronic pain of non-malignant origin ......................................................................................... 128
Transdermal local anesthetics ...................................................................................................... 129
Postoperative pain ....................................................................................................................... 129
Transdermal fentanyl for the management of postoperative pain .............................................. 129
Fibromyalgia ................................................................................................................................... 129
Nanotechnology-based approved transdermal analgesic preparations ...................................... 130

Nausea and vomiting ................................................................................................................... 130
Motion sickness ........................................................................................................................... 130
Postoperative vomiting ............................................................................................................... 130
Chemotherapy-induced nausea and vomiting ............................................................................ 130

Antiaging strategies ...................................................................................................................... 131
Smoking cessation ................................................................. 131
Transdermal nicotine replacement ............................................. 131
Use of nicotine patch for smoking cessation in pregnancy .............. 132
Other methods of nicotine replacement .................................... 132
Other treatments for smoking cessation .................................... 133

Miscellaneous uses of transdermal drug delivery .......................... 133
Allergic rhinitis ........................................................................ 133
Chronic fatigue syndrome ....................................................... 133
Delivery of cannabinoids ...................................................... 134
Overactive bladder and urinary incontinence ............................... 135
Transdermal oxybutynin .......................................................... 135
Viral infections ......................................................................... 136
Transdermal nanoparticles for immune enhancement in HIV ......... 136
Transdermal IQP-0410 for HIV/AIDS ......................................... 137
Wound healing and ulcers ....................................................... 137

Transdermal gene therapy ....................................................... 138
Transdermal delivery of plasmid DNA by electroporation ............... 138
Transdermal gene therapy for drug addiction ............................... 138
Transdermal antisense therapy ................................................. 139
Transdermal vaccination .......................................................... 139
The skin as an immune organ ................................................... 140
Technologies for transdermal vaccination ................................... 140
Dissolvable microneedle array for vaccine delivery ...................... 140
Electroporation for administering DNA vaccines ....................... 140
High-density microarray patch for influenza vaccine .................... 141
Microneedles for transdermal delivery of vaccines ....................... 142
Needle-free delivery of vaccines .............................................. 143
Transcutaneous immunotherapy using nanodispersions ................ 144
Applications of transdermal vaccination .................................... 144
HIV/AIDS vaccination by topical application ............................. 144
Transdermal DNA influenza vaccine ......................................... 145
Transdermal AB vaccination for Alzheimer’s disease .................... 145
Transdermal vaccination for traveler’s diarrhoea ......................... 145

Epicutaneous desensitization for food allergy ............................. 146
Peanut patch for peanut allergy .............................................. 148

Transdermal nutraceuticals ....................................................... 148

Complications of transdermal therapy ....................................... 148
Adverse effects of drugs .......................................................... 148
Overdose effect ....................................................................... 149
Skin complications ................................................................... 149
MRI-induced skin burns from transdermal patches ...................... 149

4. Markets for Transdermal Drug Delivery ................................. 152
Introduction ........................................................................... 152
Global markets for drug delivery .............................................. 152
Geographical distribution of transdermal drug delivery markets ........ 153
Emerging transdermal drug delivery markets in Asia ..................... 153
Transdermal technology markets in therapeutic areas .................... 153
Angina pectoris ........................................................................ 154
Attention deficit hyperactivity disorder ..................................... 154
Erectile dysfunction .................................................................. 155
Hypertension ......................................................................... 155
Osteoporosis .......................................................................... 155
Pain therapeutics .................................................................... 155
Parkinson’s disease .................................................................. 155
Smoking cessation .................................................................... 156
Transdermal hormone replacement therapy for menopause .......... 156
Transdermal testosterone replacement therapy for hypogonadism in the male ........................................ 156
Transdermal contraceptive market ............................................ 156
Markets according to transdermal technologies .......................... 157
Markets for microneedle-based transdermal drug delivery .............. 157
Marketing strategies for transdermal drug delivery ....................... 157
Marketing advantages of transdermal drug delivery ..................... 158
Unmet needs in transdermal drug delivery ................................... 158
Regulatory aspects that affect transdermal drug delivery ............... 159
Future prospects of transdermal drug delivery ............................. 160
Growth of new technologies used in transdermal drug delivery ....... 160
Prospects of transdermal delivery for drugs coming off patents .......... 160
Transdermal delivery of biologics .............................................. 161
Transdermal delivery of cosmetics ............................................ 161
5. Companies involved in transdermal drug delivery ........................................ 162
    Profiles of companies .................................................................................. 162
    Top companies in transdermal drug delivery .............................................. 162
    Collaborations .............................................................................................. 281

6. References .................................................................................................. 286

Tables

Table 1-1: Historical landmarks in the development of transdermal drug delivery ................. 12
Table 1-2: Transdermal vs oral and intravenous drug delivery ........................................ 14
Table 1-3: Size ranges of molecules that can be delivered by transdermal route .................... 17
Table 2-1: Technologies for transdermal drug delivery .................................................. 20
Table 2-2: Chemical enhancers of skin penetration ....................................................... 24
Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch ............................ 31
Table 2-4: Companies with transdermal patches for drug delivery .................................... 32
Table 2-5: Companies with technologies for drug delivery by iontophoresis ...................... 42
Table 2-6: Companies involved in electroperoration-based drug delivery ......................... 45
Table 2-7: Companies developing microneedles for transdermal drug delivery .................. 63
Table 2-8: Comparison of transdermal drug delivery systems ........................................ 71
Table 3-1: Approved transdermal products .................................................................... 78
Table 3-2: Transdermal drugs in clinical trials or approval process ................................... 80
Table 3-3: Companies developing devices for transdermal insulin delivery ....................... 109
Table 3-4: Selected transdermal systems GLP-1 antidiabetic agents ............................... 110
Table 4-1: Worldwide drug delivery market growth 2019 to 2029 .................................... 152
Table 4-2: Transdermal drug delivery markets for geographical regions 2019 to 2029 ........ 153
Table 4-3: Markets for transdermal products for therapeutic areas 2019-2029 .................. 154
Table 4-4: Markets according to transdermal technologies 2019-2029 ........................... 157
Table 4-5: Marketing strategies based on transdermal drug delivery technologies ............... 159
Table 5-1: Top five companies in transdermal drug delivery .......................................... 162
Table 5-2: Collaborations in transdermal drug delivery ................................................ 281

Figures

Figure 1-1: Basic structure of the skin ....................................................................... 13
Figure 1-2: Passages of transcutaneous drug absorption ............................................. 14
Figure 1-3: Events governing transcutaneous drug absorption ....................................... 16
Figure 2-1: Basic structure and function of transdermal drug delivery systems ............... 30
Figure 2-2: Transdermal system for delivery of liquid drugs .......................................... 31
Figure 2-3: Crystal Reservoir System of Nitto Denko ................................................... 37
Figure 2-4: A schematic view of electroporation......................................................... 38
Figure 2-5: Depiction of breakdown of the stratum corneum during electroporation .......... 39
Figure 2-6: A schematic drawing of Iontophoresis ....................................................... 40
Figure 2-7: SonoPrep ultrasonic skin permeation ....................................................... 48
Figure 2-8: A schematic sketch of PowderJet gas gun .................................................. 51
Figure 2-9: Drug delivery using different types of microneedles (MN) ......................... 53
Figure 2-10: A schematic drawing of the microneedle patch .......................................... 58
Figure 2-11: Preparation of solid-in-oil nanodispersion for transdermal application ......... 67
Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease ........ 91
Figure 3-2: Control functions and user interface of insulin patch monitoring system ........ 108
Figure 3-3: Transcutaneous immunotherapy using nanodispersions ............................. 144
Figure 3-4: Mechanism of action of epicutaneous immunotherapy ............................... 147
Figure 4-1: Unmet needs in transdermal drug delivery ................................................ 159